Mark Pierce, MD
Infectious Disease · Cookeville, TNNPI 1053388561
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $212,049 of the $246,116 with a category attached, or 86.2%. AbbVie accounts for 92.4% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $73,066 and has fallen 88.6% since, to $8,348 in 2025. Among infectious disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 461 payments — averaging $533.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$227K
- Melinta Therapeutics, LLC$18K
- Insmed, Inc.$296
- Merck$166
- KCI USA, Inc.$94
- Cumberland Pharmaceuticals, Inc.$82
- plus $490 from 13 others
What the payments were for
- Consulting fees$2,7751%
- Speaking & faculty fees$212,04986%
- Travel & lodging$24,54510%
- Food & beverage$6,4993%
- Education$2480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 372 | $227,335 |
| Melinta Therapeutics, LLC | 36 | $17,653 |
| Insmed, Inc. | 13 | $296 |
| Merck | 10 | $166 |
| KCI USA, Inc. | 1 | $94 |
| Cumberland Pharmaceuticals, Inc. | 5 | $82 |
| Angiodynamics, Inc. | 1 | $75 |
| Paratek Pharmaceuticals, Inc. | 4 | $67 |
| Novartis | 2 | $60 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $54 |
| Johnson & Johnson(2 entities) | 2 | $38 |
| AstraZeneca(2 entities) | 2 | $36 |
| Vifor Pharma, Inc. | 2 | $35 |
| Mallinckrodt Enterprises LLC | 2 | $29 |
| Corcept Therapeutics | 2 | $25 |
| Heartflow, Inc. | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $17 |
| Biosense Webster, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$246,116 in reported general payments places this provider in the 95th percentile of 156 infectious disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefadroxil | 31 | $1,553 |
| Minocycline Hcl | 17 | $478 |
| Doxycycline Hyclate | 15 | $270 |
| Fluconazole | 11 | $173 |
| Isoniazid | 14 | $84 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Cookeville
- Michael GelfandMemphis$486K
- Kerry ClevelandMemphis$426K
- Michael DeckerBaxter$108K
- James SizemoreChattanooga$101K
- John KoetheNashville$91K
- Elizabeth PhillipsNashville$71K
- Kassem BourgiNashville$34K
- Stephen ThrelkeldMemphis$27K
- Celestine WanjallaNashville$24K
- Imad OmerMemphis$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.